Home > Haematology > EHA 2019 > Myeloma > CASSIOPEIA trial: Phase 3 results of daratumumab + bortezomib/thalidomide/dexamethasone in multiple myeloma

CASSIOPEIA trial: Phase 3 results of daratumumab + bortezomib/thalidomide/dexamethasone in multiple myeloma

Presented By
Prof. Phillippe Moreau, University Hospital of Nantes, France
Conference
EHA 2019
Trial
Phase 3, CASSIOPEIA
The addition of daratumumab to the triplet bortezomib, thalidomide, and dexamethasone (VTd) induction and consolidation in transplant-eligible patients with newly diagnosed multiple myeloma improved both the depth of response and progression-free survival (PFS) compared with VTd alone [1]. Prof. Phillippe Moreau (University Hospital of Nantes, France) discussed the findings from the randomised, open-label, multicentre, phase 3 CASSIOPEIA trial and the potential role for daratumumab in patients with newly diagnosed multiple myeloma in combination with standard-of-care VTd for patients who are candidates for autologous stem cell transplantation (ASCT). Patients (n=1,085) were enrolled and randomly assigned to VTd induction and consolidation either with (n=543) or without (n=542) the addition of daratumumab (Dara-VTd) followed by high-dose melphalan and ASCT. T...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on